Skip to main content
NCBI home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2009 Nov 12;32(10):544–548. doi: 10.1002/clc.20669

Statins as Antiarrhythmics: A Systematic Review Part I: Effects on Risk of Atrial Fibrillation

Hussam Abuissa 1,✉, James H O'Keefe 1,2, Kevin A Bybee 1,2
PMCID: PMC6652890  PMID: 19911349

Abstract

Background

Recent studies have demonstrated that statins may possess antiarrhythmic properties in addition to their lipid‐lowering effects.

Methods

Studies which reported the association of statins with the incidence of atrial arrhythmias were identified through a systematic review of published literature.

Results

One randomized, placebo‐controlled trial of 200 patients undergoing cardiac surgery showed that atorvastatin decreased the incidence of postoperative atrial fibrillation by 61%. Observational studies in patients with stable coronary disease, left ventricular dysfunction, or those undergoing cardiac or noncardiac surgery show that statin therapy is associated with an approximately 50% lower rate of atrial fibrillation. Two small randomized trials reported conflicting results: one showing that atorvastatin reduced the recurrence of AF after electrical cardioversion and the other finding that pravastatin did not.

Conclusions

Published data suggests that statins may possess antiarrhythmic properties that reduce the propensity for atrial fibrillation. Most of this data is observational; more randomized, placebo‐controlled trials are needed. Copyright © 2009 Wiley Periodicals, Inc.

Full Text

The Full Text of this article is available as a PDF (160.4 KB).

References

  • 1. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335(14): 1001–1009. [DOI] [PubMed] [Google Scholar]
  • 2. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high‐risk individuals: a randomised placebo‐controlled trial. Lancet 2002; 360(9326): 7–22. [DOI] [PubMed] [Google Scholar]
  • 3. Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1998; 98(9): 839–844. [DOI] [PubMed] [Google Scholar]
  • 4. Notarbartolo A, Davi G, Averna M, et al. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. Arterioscler Thromb Vasc Biol 1995; 15(2): 247–251. [DOI] [PubMed] [Google Scholar]
  • 5. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG‐coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997; 95(5): 1126–1131. [DOI] [PubMed] [Google Scholar]
  • 6. Young‐Xu Y, Jabbour S, Goldberg R, et al. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am J Cardiol 2003; 92(12): 1379–1383. [DOI] [PubMed] [Google Scholar]
  • 7. Marin F, Pascual DA, Roldan V, et al. Statins and postoperative risk of atrial fibrillation following coronary artery bypass grafting. Am J Cardiol 2006; 97(1): 55–60. [DOI] [PubMed] [Google Scholar]
  • 8. Dotani MI, Elnicki DM, Jain AC, Gibson CM. Effect of preoperative statin therapy and cardiac outcomes after coronary artery bypass grafting. Am J Cardiol 2000; 86(10): 1128–1130, A1126. [DOI] [PubMed] [Google Scholar]
  • 9. Patti G, Chello M, Candura D, et al. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA‐3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study. Circulation 2006; 114(14): 1455–1461. [DOI] [PubMed] [Google Scholar]
  • 10. Amar D, Zhang H, Heerdt PM, Park B, Fleisher M, Thaler HT. Statin use is associated with a reduction in atrial fibrillation after noncardiac thoracic surgery independent of C‐reactive protein. Chest 2005; 128(5): 3421–3427. [DOI] [PubMed] [Google Scholar]
  • 11. Siu CW, Lau CP, Tse HF. Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. Am J Cardiol 2003; 92(11): 1343–1345. [DOI] [PubMed] [Google Scholar]
  • 12. Tveit A, Grundtvig M, Gundersen T, et al. Analysis of pravastatin to prevent recurrence of atrial fibrillation after electrical cardioversion. Am J Cardiol 2004; 93(6): 780–782. [DOI] [PubMed] [Google Scholar]
  • 13. Ozaydin M, Varol E, Aslan SM, et al. Effect of atorvastatin on the recurrence rates of atrial fibrillation after electrical cardioversion. Am J Cardiol 2006; 97(10): 1490–1493. [DOI] [PubMed] [Google Scholar]
  • 14. Hanna IR, Heeke B, Bush H, et al. Lipid‐lowering drug use is associated with reduced prevalence of atrial fibrillation in patients with left ventricular systolic dysfunction. Heart Rhythm 2006; 3(8): 881–886. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 1998; 279(20): 1643–1650. [DOI] [PubMed] [Google Scholar]
  • 16. Aranki SF, Shaw DP, Adams DH, et al. Predictors of atrial fibrillation after coronary artery surgery. Current trends and impact on hospital resources. Circulation 1996; 94(3): 390–397. [DOI] [PubMed] [Google Scholar]
  • 17. Atrial fibrillation: current understandings and research imperatives. The National Heart, Lung, and Blood Institute Working Group on Atrial Fibrillation. J Am Coll Cardiol 1993; 22(7): 1830–1834. [PubMed] [Google Scholar]
  • 18. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population‐based cohort. The Framingham Heart Study. JAMA 1994; 271(11): 840–844. [PubMed] [Google Scholar]
  • 19. Cha YM, Redfield MM, Shen WK, Gersh BJ. Atrial fibrillation and ventricular dysfunction: a vicious electromechanical cycle. Circulation 2004; 109(23): 2839–2843. [DOI] [PubMed] [Google Scholar]
  • 20. Ehrlich JR, Nattel S, Hohnloser SH. Atrial fibrillation and congestive heart failure: specific considerations at the intersection of two common and important cardiac disease sets. J Cardiovasc Electrophysiol 2002; 13(4): 399–405. [DOI] [PubMed] [Google Scholar]
  • 21. Lloyd‐Jones DM, Wang TJ, Leip EP, et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 2004; 110(9): 1042–1046. [DOI] [PubMed] [Google Scholar]
  • 22. Amar D. Perioperative atrial tachyarrhythmias. Anesthesiology 2002; 97(6): 1618–1623. [DOI] [PubMed] [Google Scholar]
  • 23. Amar D, Zhang H, Leung DH, Roistacher N, Kadish AH. Older age is the strongest predictor of postoperative atrial fibrillation. Anesthesiology 2002; 96(2): 352–356. [DOI] [PubMed] [Google Scholar]
  • 24. Polanczyk CA, Goldman L, Marcantonio ER, Orav EJ, Lee TH. Supraventricular arrhythmia in patients having noncardiac surgery: clinical correlates and effect on length of stay. Ann Intern Med 1998; 129(4): 279–285. [DOI] [PubMed] [Google Scholar]
  • 25. Mihm MJ, Yu F, Carnes CA, et al. Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation 2001; 104(2): 174–180. [DOI] [PubMed] [Google Scholar]
  • 26. Takemoto M, Node K, Nakagami H, et al. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest 2001; 108(10): 1429–1437. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998; 97(12): 1129–1135. [DOI] [PubMed] [Google Scholar]
  • 28. Li W AT, McTaggart F, Tsao P. Rosuvastatin inhibits monocyte/ endothelial interactionsin ApoE (−/−) mice. Int J Clin Pract 2002; 24(Suppl): 5. [Google Scholar]
  • 29. Giroux LM, Davignon J, Naruszewicz M. Simvastatin inhibits the oxidation of low‐density lipoproteins by activated human monocyte‐derived macrophages. Biochim Biophys Acta 1993; 1165(3): 335–338. [DOI] [PubMed] [Google Scholar]
  • 30. Conway DS, Buggins P, Hughes E, Lip GY. Relationship of interleukin‐6 and C‐reactive protein to the prothrombotic state in chronic atrial fibrillation. J Am Coll Cardiol 2004; 43(11): 2075–2082. [DOI] [PubMed] [Google Scholar]
  • 31. Tziakas DN, Chalikias GK, Stakos DA, et al. Effect of statins on collagen type I degradation in patients with coronary artery disease and atrial fibrillation. Am J Cardiol 2008; 101(2): 199–202. [DOI] [PubMed] [Google Scholar]
  • 32. Wazni O, Martin DO, Marrouche NF, et al. C reactive protein concentration and recurrence of atrial fibrillation after electrical cardioversion. Heart 2005; 91(10): 1303–1305. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33. Xu J, Cui G, Esmailian F, et al. Atrial extracellular matrix remodeling and the maintenance of atrial fibrillation. Circulation 2004; 109(3): 363–368. [DOI] [PubMed] [Google Scholar]
  • 34. Healey JS, Baranchuk A, Crystal E, et al. Prevention of atrial fibrillation with angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers: a meta‐analysis. J Am Coll Cardiol 2005; 45(11): 1832–1839. [DOI] [PubMed] [Google Scholar]
  • 35. Mozaffarian D, Psaty BM, Rimm EB, et al. Fish intake and risk of incident atrial fibrillation. Circulation 2004; 110(4): 368–373. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES